Amgen (NASDAQ:AMGN) Price Target Raised to $208.00

Amgen (NASDAQ:AMGNGet Rating) had its price target hoisted by Mizuho from $202.00 to $208.00 in a report published on Tuesday morning, The Fly reports.

Several other analysts have also recently issued reports on the company. Oppenheimer cut Amgen to an outperform rating and set a $285.00 price objective on the stock. in a research note on Tuesday, May 3rd. Barclays increased their target price on Amgen from $233.00 to $236.00 and gave the company an equal weight rating in a report on Tuesday, April 12th. BMO Capital Markets reduced their target price on Amgen from $263.00 to $243.00 in a report on Thursday, April 28th. StockNews.com lowered Amgen from a strong-buy rating to a buy rating in a report on Tuesday, April 5th. Finally, Jefferies Financial Group increased their target price on shares of Amgen from $266.00 to $280.00 and gave the stock a buy rating in a research report on Wednesday, February 9th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Amgen currently has a consensus rating of Hold and a consensus target price of $240.40.

Shares of NASDAQ:AMGN opened at $243.40 on Tuesday. The company has a market cap of $130.02 billion, a P/E ratio of 23.96, a P/E/G ratio of 1.68 and a beta of 0.58. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. Amgen has a 52 week low of $198.64 and a 52 week high of $258.45. The business has a fifty day simple moving average of $241.68 and a 200-day simple moving average of $227.38.

Amgen (NASDAQ:AMGNGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $4.22 by $0.03. Amgen had a return on equity of 165.95% and a net margin of 21.75%. The business had revenue of $6.24 billion during the quarter, compared to the consensus estimate of $6.09 billion. During the same quarter in the previous year, the business earned $3.70 earnings per share. Sell-side analysts expect that Amgen will post 17.49 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Shareholders of record on Tuesday, May 17th will be given a dividend of $1.94 per share. The ex-dividend date of this dividend is Monday, May 16th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.19%. Amgen’s payout ratio is presently 76.38%.

In other Amgen news, EVP Jonathan P. Graham sold 13,500 shares of the stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the transaction, the executive vice president now owns 37,333 shares in the company, valued at approximately $9,027,492.73. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.46% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Amgen by 2.1% during the 4th quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock worth $11,258,926,000 after acquiring an additional 1,032,929 shares during the period. Vanguard Group Inc. lifted its stake in Amgen by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 47,329,045 shares of the medical research company’s stock valued at $11,445,110,000 after purchasing an additional 668,036 shares during the last quarter. State Street Corp lifted its stake in Amgen by 1.7% in the 4th quarter. State Street Corp now owns 30,147,007 shares of the medical research company’s stock valued at $6,782,172,000 after purchasing an additional 505,306 shares during the last quarter. Geode Capital Management LLC lifted its stake in Amgen by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 10,362,110 shares of the medical research company’s stock valued at $2,198,289,000 after purchasing an additional 367,936 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Amgen by 0.8% in the 2nd quarter. Morgan Stanley now owns 10,040,932 shares of the medical research company’s stock valued at $2,447,476,000 after purchasing an additional 80,922 shares during the last quarter. 79.01% of the stock is owned by institutional investors.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

The Fly logo

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.